{"title":"Targeted Biologic Strategies in Eosinophilic COPD: A Narrative Review of Mepolizumab and Dupilumab within a Precision Medicine Framework.","authors":"Ojus Sardana, Varsha Raj","doi":"10.2174/0115748871508018261028100854","DOIUrl":"https://doi.org/10.2174/0115748871508018261028100854","url":null,"abstract":"<p><p>Chronic Obstructive Pulmonary Disease (COPD) remains a significant global health concern, causing progressive airflow obstruction, frequent acute exacerbations, and severely impaired Quality of Life (QoL) despite using optimised inhaled maintenance therapy. The previously accepted perception of COPD as a pathophysiologically homogeneous disease was called into question, as immunological heterogeneity could be observed among patients, particularly a type 2 inflammatory endotype with high Blood Eosinophil Counts (BEC) as a subgroup with specific prognostic and therapeutic implications. These developments shifted the clinical mindset from non-specific bronchodilators to mechanism-based, cytokine-targeted interventions tailored to each patient's inflammatory biomarker. The current review presents an in-depth assessment of two monoclonal antibodies (mAbs) that have obtained regulatory approval for the eosinophilic COPD phenotype, namely mepolizumab, a humanised IgG1 antibody that neutralises circulating IL-5, and dupilumab, a fully human IgG4 antibody that binds to the shared IL-4 receptor alpha subunit (IL-4Rα) and thus simultaneously inhibits both IL-4 and IL-13 downstream signalling pathways. The review also discusses the mechanistic and clinical differences between the two agents, including dosing aspects and pharmacoeconomic limitations to universal use, as well as the usefulness of peripheral eosinophilia as a biomarker to select patients. It further explores additional areas of future therapy, including upstream alarmin blockade and combinatorial biologic strategies within a precision medicine paradigm, and highlights the urgent need for real-world evidence to inform the equitable integration of these therapies into routine COPD management pathways.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149410139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Corrigendum to: Effect of Kangaroo Mother Care on Successful Breastfeeding: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.","authors":"Morteza Ghojazadeh, Sakineh Hajebrahimi, Fatemeh Pournaghi-Azar, Mohammad Mohseni, Naser Derakhshani, Saber Azami-Aghdash","doi":"10.2174/1574887122999261103102009","DOIUrl":"https://doi.org/10.2174/1574887122999261103102009","url":null,"abstract":"<p><p>Following publication of the article entitled: \"Effect of Kangaroo Mother Care on Successful Breastfeeding: A Systematic Review and Meta-Analysis of Randomised Controlled Trials\" [1], the authors were notified by a reader of duplicate entries in Table 2. Upon verification, it was confirmed that the following studies had been inadvertently listed twice: • Roberts et al. (2000) - Reference [13] • Carfoot et al. (2005) - Reference [14] • Morelius et al. (2015) - Reference [15] This correction is limited to the presentation of the study entries in Table 2 and does not affect the findings or conclusions of the article. The original article has been updated accordingly. This corrigendum is published to ensure transparency and accuracy of the scholarly record. The corrected version of the article is available online at: https://www.eurekaselect.com/article/93194 The authors regret these errors and apologise for any inconvenience they may have caused.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149387669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Clinicodemographic Profile and Determinants Associated with Outcomes Among Patients with Benign Prostatic Hyperplasia in Mangalore City of South India: A Retrospective Multi-hospital-based Study.","authors":"Nitin Joseph, Prajwal P Ravinder, Aishwariya Lakshmi Narasimhan, Kaushiki Jain, Ananya Rai, Vibhuti Kumar, Shreyash Varshney, Saksham Arora, Abhay Lalit Goel, Amreen Hussain","doi":"10.2174/0115748871499439260807055703","DOIUrl":"https://doi.org/10.2174/0115748871499439260807055703","url":null,"abstract":"<p><strong>Introduction: </strong>Benign Prostatic Hyperplasia (BPH) is a common cause of Lower Urinary Tract Symptoms (LUTS) among ageing men. This study was therefore conducted to study the clinical features, complications, and management practices of BPH. Also, it was done to identify the determinants associated with increased symptom severity, complications, and non-recovery status among BPH patients.</p><p><strong>Methods: </strong>This retrospective study used one year of data collected from the medical records of 156 BPH inpatients at two tertiary care hospitals in Mangalore. Determinants of the outcome variables, severity of International Prostate Symptom Score (IPSS), complications, and non-recovery status following management, were assessed using the binary logistic regression analysis model.</p><p><strong>Results: </strong>The mean age of the patients was 66.5 (SD 12.2) years. The mean age at diagnosis was 65.6 (SD 11.9) years. IPSS suggestive of moderate-to-severe BPH was present among 111 (71.1%) patients. The most common complication of BPH was urinary tract infection [36 (23.1%)]. Seventynine (50.6%) patients were on pharmacological management. Seventy-seven (49.4%) patients were on surgical management. Among them, 76 (98.7%) underwent Transurethral Resection Of The Prostate (TURP). Severe IPSS was more common among BPH patients with diabetes mellitus (DM) (p =0.015). Complications such as renal failure (p =0.03), bladder diverticula (p =0.003), increased Blood Urea Nitrogen (BUN) (p =0.006), and serum hyponatremia (p =0.031) were associated with severe IPSS. The nonrecovery status following management was significantly greater among those with below-poverty-line status (p =0.042), dyslipidaemia (p =0.004), and bladder diverticula (p =0.006).</p><p><strong>Discussion: </strong>There is a need to spread awareness of BPH, particularly among middle-aged men, regarding its common signs and symptoms observed in this study, so that they can seek timely healthcare services. Considering the high prevalence of DM currently seen among males in India, it becomes essential to identify BPH among them, as DM was associated with the increased severity of BPH. Increased risk of life-threatening complications such as renal failure and increased BUN among patients with severe BPH further emphasizes the need for its early identification and timely management.</p><p><strong>Conclusion: </strong>The mean age of BPH diagnosis was delayed. Therefore, people, particularly those in high-risk groups, need to be made aware of their symptoms and signs to seek early treatment. The IPSS was moderate-to-severe among the majority of BPH patients, possibly indicating their delayed health-seeking behaviour. Several determinants were found to influence outcomes in BPH patients, which need to be controlled for a better prognosis following management.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149335120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Advances in Biomarkers and Novel Therapeutics in Renal Cell Carcinoma: Evidence from Recent Clinical Trials.","authors":"Bida Joshua John, Shoma Mukherjee, Pallavi Prasad, Anisha Adya, Ratnakar Shukla","doi":"10.2174/0115748871512585261007153038","DOIUrl":"https://doi.org/10.2174/0115748871512585261007153038","url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is the most common renal malignancy in adults. Owing to its high incidence, asymptomatic presentation, late diagnosis, and resistance to conventional therapies, it is associated with significant morbidity and mortality. However, current clinical trials focus more on identifying suitable molecular biomarkers and evaluating new treatments, such as targeted agents and immunotherapy. This review highlights novel biomarkers and recent clinical trials for the therapeutic management of patients with RCC. A comprehensive literature review was conducted using databases such as Web of Science, MEDLINE, Scopus, PubMed, and ClinicalTrials.gov (https://clinicaltrials.gov/) on novel biomarkers and various clinical trials for RCC. Recent clinical trials have shown a significant increase in biomarker discovery, including DNA methylation, microRNAs, long non-coding RNAs, and protein-based markers, which influence diagnosis, prognosis, and treatment. The treatment of RCC has progressed from cytokine-based immunotherapy to targeted therapies, such as mTOR and VEGF inhibitors, immune checkpoint inhibitors, and combination regimens, which have greatly improved patient outcomes. Emerging approaches, including novel immunological targets, adoptive cell therapies, vaccines, and oncolytic virotherapy, hold promise for overcoming resistance and boosting efficacy, and are currently being investigated in clinical trials. Despite these developments, intratumoral heterogeneity, lack of prognostic biomarkers, disparities in clinical trials, and treatment resistance are major limitations. Ongoing research and clinical trials focused on biomarker-driven precision medicine and combination approaches are expected to improve RCC management significantly. Validation through large multicenter trials will be necessary to enable the use of biomarkers for precision medicine in routine practice.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Simona Paola Tiburzi, Rosetta Nistico', Vincenzo Stivala, Archina De Luca, Isora Justiz-Pérez, Antonella Putignano, Virginia Vescio
{"title":"Severe Hypoxic-ischaemic Encephalopathy and Takotsubo Cardiomyopathy Following Accidental Butane Exposure: A Case Report.","authors":"Simona Paola Tiburzi, Rosetta Nistico', Vincenzo Stivala, Archina De Luca, Isora Justiz-Pérez, Antonella Putignano, Virginia Vescio","doi":"10.2174/0115748871514679261009113338","DOIUrl":"https://doi.org/10.2174/0115748871514679261009113338","url":null,"abstract":"<p><strong>Background: </strong>Butane is a highly lipophilic aliphatic hydrocarbon widely used as a domestic fuel and aerosol propellant. Acute exposure in enclosed environments may cause severe neurological and cardiovascular toxicity through oxygen displacement, respiratory depression, myocardial sensitisation to catecholamines, and potentially direct toxic effects.</p><p><strong>Case presentation: </strong>A 45-year-old woman was found unconscious in a small, closed studio apartment, while her husband was found deceased in the same environment. Subsequent inspection by the judicial authorities identified deterioration of the gas tubing associated with a gas leak. The patient presented in deep coma (Glasgow Coma Scale score 5) and required tracheal intubation and mechanical ventilation. Initial carboxyhaemoglobin was 16.9% and progressively normalised during oxygen therapy. Brain imaging demonstrated extensive cortical, deep grey matter, brainstem, cerebellar, and white-matter abnormalities consistent with severe hypoxic-ischaemic injury. Cardiac evaluation showed mild ST-segment elevation, increased cardiac biomarkers, and severe transient Left Ventricular Systolic Dysfunction (LVEF 25%) with a pattern highly suggestive of Takotsubo cardiomyopathy; LVEF subsequently improved to 44%. Severe neurological impairment persisted, and the patient was transferred to neurological rehabilitation. She died approximately six months after the index event; reliable documentation of the precise cause of death was unavailable.</p><p><strong>Conclusion: </strong>This case illustrates the severe neurological and cardiovascular consequences that may follow accidental butane exposure in an enclosed environment. The coexistence of extensive hypoxic- ischaemic brain injury and transient stress-related ventricular dysfunction highlights the importance of integrated neurological, cardiological, and toxicological assessment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149220673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Recent Advances in Pharmacological Interventions for Huntington's Disease: Evidence from Clinical Translation.","authors":"Varsha Raj, Mohit Gupta, Neerja Kumari, Anubha Gaur, Mukesh Chandra Sharma, Varsha Snehi, Rahul Yadav, Shivendra Kumar, Jeetendra Kumar Gupta","doi":"10.2174/0115748871503552261008112411","DOIUrl":"https://doi.org/10.2174/0115748871503552261008112411","url":null,"abstract":"<p><p>Huntington's Disease (HD) is a rare autosomal dominant neurodegenerative disorder characterized by progressive motor dysfunction, psychiatric disturbances, and cognitive decline. An expanded CAG trinucleotide repeat in the Huntingtin (HTT) gene causes it to repeat, leading to the production of mutant Huntingtin Protein (mHTT), which drives selective neuronal degeneration, particularly in the striatum and cortex. Despite the identification of its genetic basis over three decades ago, HD remains incurable, with current therapies largely limited to symptomatic management. This review provides a comprehensive overview of emerging pharmacological strategies targeting the underlying molecular and cellular mechanisms of HD, with emphasis on translational insights from recent and ongoing clinical trials. Key pathogenic processes, including protein aggregation, transcriptional dysregulation, impaired proteostasis, mitochondrial dysfunction, synaptic deficits, and chronic neuroinflammation, are discussed to contextualize therapeutic approaches. Genetargeting strategies, including Antisense Oligonucleotides (ASOs), RNA interference (RNAi), and small-molecule splicing modulators, have demonstrated effective suppression of mutant huntingtin expression and favorable biomarker responses. However, despite robust target engagement, these molecular effects have not consistently translated into sustained clinical benefit, highlighting the complexity of achieving disease modification in Huntington's disease. Similarly, therapies targeting neuroinflammation, autophagy, mitochondrial dysfunction, and synaptic signaling have shown encouraging preclinical efficacy but only limited clinical success. The review highlights the critical role of biomarkers, including cerebrospinal fluid mHTT, neurofilament light chain, and imaging markers, in evaluating therapeutic efficacy, while underscoring the uncertainty in their correlation with long-term clinical outcomes. Persistent challenges in clinical translation emphasize the need for precision-based, stage-specific therapeutic strategies to achieve meaningful disease modification. Unlike previous reviews, this article critically integrates recent clinical trial outcomes with translational challenges, biomarker validation, regulatory perspectives, and future precision-medicine strategies, providing a comprehensive overview of the evolving therapeutic landscape for Huntington's disease.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anuradha Singh, Prottay Dutta, Mohammad Muztaba, Swagatam Sahoo, Pooja Ganeshdas Bhutada, Manju, K P Selma Thasni, Binita Ghosh, Rahul Pal
{"title":"Genital Tuberculosis (GTB): Insights into Diagnosis, Treatment, Clinical Trials and Patents-A Comprehensive Review.","authors":"Anuradha Singh, Prottay Dutta, Mohammad Muztaba, Swagatam Sahoo, Pooja Ganeshdas Bhutada, Manju, K P Selma Thasni, Binita Ghosh, Rahul Pal","doi":"10.2174/0115748871502522261008104215","DOIUrl":"https://doi.org/10.2174/0115748871502522261008104215","url":null,"abstract":"<p><p>Genital Tuberculosis (GTB) represents a frequently unrecognized type of extrapulmonary Tuberculosis (TB) that affects the female reproductive system. The condition results in infertility, menstrual cycle disturbances, and pelvic pain. The condition is difficult to detect at an early stage because its mild symptoms can manifest in different body parts. Therefore, medical professionals require better methods for diagnosing and treating patients. This review aims to provide a comprehensive overview of the epidemiology, pathogenesis, clinical manifestations, diagnostic approaches, therapeutic strategies, and current advancements in the management of GTB. The study presents information on New Drug Delivery systems (NDDs), current clinical trials, and new patents to guide future research. A literature-based narrative review was conducted, focusing on peer-reviewed articles, clinical studies, patents, and recent advances in diagnostics and therapeutics of GTB. The study focused on three main areas: anatomical site-specific manifestations; laboratory instruments and drug medications. The fallopian tubes are the most commonly affected site (90-100%), followed by the endometrium (50-60%), ovaries (20-30%), cervix (5-10%), while involvement of the vagina and vulva is rare (<1%). The diagnosis of GTB becomes problematic because both its visible and hidden symptoms start to appear. The development of effective detection methods depends on both traditional diagnostic methods and modern molecular methods, which include specialized laboratory equipment, imaging techniques, and histopathology. Current clinical trials and new patent approvals demonstrate the development of new methods for diagnosing and treating GTB, including improved therapeutic approaches and drug delivery systems. GTB presents both diagnostic and treatment difficulties because patients show different symptoms that can remain hidden. The combination of methods for diagnosing and treating GTB, through improved therapeutic approaches and drug-delivery systems, will enhance detection, treatment outcomes, and the ability to maintain fertility. The research should investigate personalized medicine approaches, molecular diagnostic technologies, and new therapeutic delivery systems to address the existing clinical needs in GTB treatment.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149184161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Review Article on Smart Phyto-nanoemulgel Systems for Modulation of Inflammatory Mediators in Rheumatoid Arthritis.","authors":"Renu Tiwari, Shaweta Sharma","doi":"10.2174/0115748871495317260907100938","DOIUrl":"https://doi.org/10.2174/0115748871495317260907100938","url":null,"abstract":"<p><p>This review article offers a thorough examination of nanoemulgel-based drug delivery methods for rheumatoid arthritis (RA) treatment. The study delves into the fusion of nanotechnology with gel-based systems, underscoring their superior drug-delivery capabilities, controlled release, and targeted therapeutic potential for managing rheumatoid arthritis. It also provides a detailed exploration of the use of herbal plants in the treatment of arthritis, focusing on traditional remedies, active components, mechanisms of action, and pharmacological strategies to enhance their administration. These approaches are designed to improve bioavailability, support targeted distribution, and allow for controlled release of herbal constituents. Safety considerations, including potential drug interactions and the risk of allergic responses, are also addressed. Rheumatoid arthritis is a debilitating condition characterized by inflammation of the synovial membrane, leading to cartilage and bone degradation. Numerous medications, including anti-inflammatory drugs and disease-modifying antirheumatic therapies, can assist in its management; also, phytotherapy presents a promising and advantageous approach for treating rheumatoid arthritis, due to its capacity to target a range of inflammatory substances, such as nitric oxide (NO), cytokines, chemokines, and adhesion molecules, especially given the significant side effects associated with conventional treatments. Additionally, nanomedicine offers a valuable formulation approach to address challenges associated with phytoconstituents, including poor bioavailability, high first-pass metabolism, and reduced stability. This review provides an extensive overview of numerous phytoconstituents with significant potential in the management of RA, their limitations, innovative drug formulations reported, and the relevant regulatory considerations.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149114531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Artificial Intelligence and Generative AI in Clinical Trials for Autism and Other Neurobehavioral Disorders.","authors":"Mattia Galanti, Luigi Boccuto","doi":"10.2174/0115748871524685260904061932","DOIUrl":"https://doi.org/10.2174/0115748871524685260904061932","url":null,"abstract":"<p><p>Artificial Intelligence (AI) provides remarkable tools in modern medicine and is widely used to process high-throughput data and integrate different omics-derived models. In recent years, AI, and particularly generative AI (GenAI), has been utilized to design clinical trials for neurobehavioral disorders due to the complexity of variables presented by these conditions. However, ethical and methodological limitations suggest a supporting rather than leading role of AI in the design, management, and interpretation of clinical trials, and caution against moving the human component away from the evaluation of the qualitative as well as quantitative impact of a new treatment protocol.</p>","PeriodicalId":21174,"journal":{"name":"Reviews on recent clinical trials","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2026-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149040470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}